Aude Houchard

905 total citations
53 papers, 587 citations indexed

About

Aude Houchard is a scholar working on Epidemiology, Endocrinology, Diabetes and Metabolism and Oncology. According to data from OpenAlex, Aude Houchard has authored 53 papers receiving a total of 587 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Epidemiology, 25 papers in Endocrinology, Diabetes and Metabolism and 23 papers in Oncology. Recurrent topics in Aude Houchard's work include Neuroendocrine Tumor Research Advances (27 papers), Lung Cancer Research Studies (22 papers) and Pituitary Gland Disorders and Treatments (22 papers). Aude Houchard is often cited by papers focused on Neuroendocrine Tumor Research Advances (27 papers), Lung Cancer Research Studies (22 papers) and Pituitary Gland Disorders and Treatments (22 papers). Aude Houchard collaborates with scholars based in France, United States and United Kingdom. Aude Houchard's co-authors include Stephan Petersenn, Caroline Sert, Philippe Caron, Philippe Chanson, John S. Bevan, Шломо Мелмед, Eva Lesén, Ingela Björholt, Andrea Giustina and Daniel Granfeldt and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and Annals of Oncology.

In The Last Decade

Aude Houchard

45 papers receiving 575 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Aude Houchard France	16	356	235	194	172	137	53	587
Javier Aller Spain	15	299 0.8×	244 1.0×	210 1.1×	141 0.8×	136 1.0×	37	522
Frank J. Quayle United States	9	230 0.6×	163 0.7×	119 0.6×	95 0.6×	215 1.6×	9	423
Daniela Betea Belgium	12	321 0.9×	146 0.6×	161 0.8×	59 0.3×	180 1.3×	28	611
J.-L. Wémeau France	10	385 1.1×	148 0.6×	75 0.4×	67 0.4×	193 1.4×	31	513
Sonali Thosani United States	10	179 0.5×	162 0.7×	326 1.7×	85 0.5×	251 1.8×	23	582
Catherine Bauters France	9	231 0.6×	407 1.7×	314 1.6×	256 1.5×	147 1.1×	19	605
Roxanne Merkel United States	12	119 0.3×	173 0.7×	217 1.1×	108 0.6×	100 0.7×	16	459
M Nocaudie France	9	404 1.1×	135 0.6×	94 0.5×	99 0.6×	200 1.5×	16	543
Colleen Veloski United States	7	184 0.5×	101 0.4×	288 1.5×	53 0.3×	116 0.8×	10	477
Masatoshi Iihara Japan	16	209 0.6×	166 0.7×	228 1.2×	106 0.6×	250 1.8×	30	592

Countries citing papers authored by Aude Houchard

Since Specialization

Citations

This map shows the geographic impact of Aude Houchard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aude Houchard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aude Houchard more than expected).

Fields of papers citing papers by Aude Houchard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aude Houchard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aude Houchard. The network helps show where Aude Houchard may publish in the future.

Co-authorship network of co-authors of Aude Houchard

This figure shows the co-authorship network connecting the top 25 collaborators of Aude Houchard. A scholar is included among the top collaborators of Aude Houchard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aude Houchard. Aude Houchard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Matveev, Vsevolod, Xin Gao, Evgeny Kopyltsov, et al.. (2024). PRIORITI: Phase 4 study of triptorelin or active surveillance in high‐risk prostate cancer. Asia-Pacific Journal of Clinical Oncology. 20(6). 738–746.

Hautefeuille, Vincent, Thomas Walter, Christine Do Cao, et al.. (2023). OPERA: perception of information in patients with gastroenteropancreatic neuroendocrine tumors on lanreotide autogel. European Journal of Endocrinology. 189(2). 281–289. 2 indexed citations

Fleseriu, Maria, Ariel L. Barkan, Thierry Brue, et al.. (2023). Treatment Patterns, Adherence, Persistence, and Health Care Resource Utilization in Acromegaly: A Real-World Analysis. Journal of the Endocrine Society. 7(10). bvad104–bvad104. 7 indexed citations

Hernando, Jorge, Teodora Kolarova, Chris Verslype, et al.. (2023). Satisfaction with injection experience of patients with neuroendocrine tumors enrolled on lanreotide autogel patient support programs: Results from the international HomeLAN survey. Journal of Neuroendocrinology. 35(6). e13281–e13281. 3 indexed citations

Ferone, Diego, Wendy Martin, Jesse W. Williams, et al.. (2023). An international simulated-use study to assess nurses’ preferences between two lanreotide syringes for patients with neuroendocrine tumours or acromegaly (PRESTO 3). Journal of Endocrinological Investigation. 47(2). 421–432. 2 indexed citations

O’Toole, Dermot, et al.. (2022). PRESTO 2: An International Survey to Evaluate Patients’ Injection Experiences with the Latest Devices/Formulations of Long-Acting Somatostatin Analog Therapies for Neuroendocrine Tumors or Acromegaly. Advances in Therapy. 40(2). 671–690. 12 indexed citations

Fleseriu, Maria, et al.. (2022). A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly. Pituitary. 26(1). 9–41. 7 indexed citations

Ferollà, Piero, Alfredo Berruti, Francesca Spada, et al.. (2022). Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT Study. Neuroendocrinology. 113(3). 332–342. 16 indexed citations

Rinke, Anja, Christoph Maintz, Lothar Müller, et al.. (2021). Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria. Experimental and Clinical Endocrinology & Diabetes. 129(7). 500–509. 5 indexed citations

10.

Srirajaskanthan, Rajaventhan, et al.. (2021). Weight Maintenance up to 48 Weeks in Patients With Carcinoid Syndrome Treated With Telotristat Ethyl: Pooled Data From the Open-Label Extensions of the Phase III Clinical Trials TELESTAR and TELECAST. Clinical Therapeutics. 43(10). 1779–1785.

11.

Adelman, Daphne T., et al.. (2020). Evaluation of Nurse Preferences Between the Lanreotide Autogel New Syringe and the Octreotide Long-Acting Release Syringe: An International Simulated-Use Study (PRESTO). Advances in Therapy. 37(4). 1608–1619. 15 indexed citations

12.

Ferollà, Piero, Alfredo Berruti, Francesca Spada, et al.. (2020). 1161MO Lanreotide autogel (LAN) and temozolomide (TMZ) combination therapy in progressive thoracic neuroendocrine tumours (TNETs): ATLANT study results. Annals of Oncology. 31. S773–S773. 9 indexed citations

13.

Xie, Liyang, et al.. (2020). 664P Efficacy of triptorelin after radical prostatectomy in patients with high-risk prostate cancer. Annals of Oncology. 31. S535–S536. 1 indexed citations

14.

Lesén, Eva, Daniel Granfeldt, Aude Houchard, et al.. (2019). Treatment Patterns and Survival among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumours in Sweden - a Population-based Register-linkage and Medical Chart Review Study. Journal of Cancer. 10(27). 6876–6887. 8 indexed citations

15.

Giustina, Andrea, Marcello D. Bronstein, Philippe Chanson, et al.. (2019). Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT® validation study. Pituitary. 22(5). 476–487. 19 indexed citations

16.

Lesén, Eva, Daniel Granfeldt, Aude Houchard, et al.. (2017). Overall survival in patients diagnosed with metastatic GEP-NET in Sweden. Annals of Oncology. 28. iii4–iii4. 1 indexed citations

17.

Reidy‐Lagunes, Diane, Michael Kulke, Edward M. Wolin, et al.. (2017). PUB119 Lanreotide in Patients with Lung Neuroendocrine Tumors: The Randomized Double-Blind Placebo-Controlled International Phase 3 SPINET Study. Journal of Thoracic Oncology. 12(1). S1516–S1517. 3 indexed citations

18.

Lesén, Eva, Daniel Granfeldt, Aude Houchard, et al.. (2016). Cost-of-Illness of Acromegaly in Sweden – A Register-Linkage Population-Based Study. Value in Health. 19(7). A669–A669. 2 indexed citations

19.

Pavel, Marianne, Clarisse Dromain, Christine Massien, & Aude Houchard. (2016). Safety and efficacy of lanreotide autogel/depot (LAN) every 14 days for patients with pancreatic or midgut neuroendocrine tumours (NETs) progressing on LAN every 28 days: The prospective, international CLARINET FORTE study. Annals of Oncology. 27. vi147–vi147.

20.

Giustina, Andrea, John S. Bevan, Marcello D. Bronstein, et al.. (2015). SAGIT®: clinician-reported outcome instrument for managing acromegaly in clinical practice—development and results from a pilot study. Pituitary. 19(1). 39–49. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact